Table 1 Characteristics of included studies
From: More pilot trials could plan to use qualitative data: a meta-epidemiological study
Variable | Use of qualitative data, n (%) | Total, n (%), 227 (100) | |
|---|---|---|---|
Yes, 92 (40.5) | No, 135 (59.5) | ||
Journal, n (%) | |||
PAFS | 23 (25.0) | 19 (14.1) | 42 (18.5) |
BMJ Open | 27 (29.3) | 44 (32.6) | 71 (31.3) |
Trials | 42 (45.7) | 72 (53.3) | 114 (50.2) |
Year of publication, n (%) | |||
2013 | 13 (14.1) | 21 (15.6) | 34 (15.0) |
2014 | 13 (14.1) | 24 (17.8) | 37 (16.3) |
2015 | 16 (17.4) | 18 (13.3) | 34 (15.0) |
2016 | 21 (22.8) | 29 (21.5) | 50 (22.0) |
2017 | 29 (31.5) | 43 (31.9) | 72 (31.7) |
Region, n (%) | |||
North America | 15 (16.3) | 28 (20.7) | 43 (18.9) |
Europe | 63 (68.5) | 57 (42.2) | 120 (52.9) |
Rest of the world | 14 (15.2) | 50 (37.0) | 64 (28.2) |
Funding, n (%) | |||
Industry | 25 (28.4) | 27 (21.8) | 52 (24.5) |
Government or private | 63 (71.6) | 97 (78.2) | 160 (75.5) |
Intervention type, n (%) | |||
Pharmacological | 5 (5.4) | 30 (22.2) | 35 (15.4) |
Non-pharmacological | 83 (94.6) | 105 (77.8) | 192 (84.6) |
Feasibility outcomes (yes), n (%) | 54 (58.7) | 69 (51.1) | 123 (54.2) |
Sample size reported (yes), n (%) | 91 (98.9) | 129 (95.6) | 220 (96.9) |
Sample size, n (%) | |||
Small (n < 60) | 45 (49.5) | 98 (75.4) | 143 (64.7) |
Large (n ≥ 60) | 46 (50.5) | 32 (24.6) | 78 (35.3) |
Sample size justification, n (%)ǂ | |||
Adequate | 48 (52.7) | 51 (39.2) | 99 (44.8) |
Inadequate | 43 (47.3) | 79 (60.8) | 122 (55.2) |
Study participants interviewed | |||
Participants | 33 (35.9) | – | 33 (35.9) |
Investigators | 1 (1.1) | – | 1 (1.1) |
Staff | 15 (16.3) | – | 15 (16.3) |
Others* | 12 (13.0) | – | 12 (13.0) |